BTIG analyst Ryan Zimmerman maintained a Hold rating on Tactile Systems Technology (TCMD – Research Report) yesterday. The company’s shares ...

In a report released yesterday, Ryan Zimmerman from BTIG reiterated a Buy rating on Penumbra (PEN – Research Report), with a price target of ...

BTIG downgraded General Dynamics Corporation (NYSE:GD)to Neutral given the ongoing regulatory hurdles and supply chain disruptions that could hamper growth in 2025.

Globus Medical Inc. (NYSE:GMED), a medical device company with a market capitalization of $12 billion and an "GREAT" financial health rating according to InvestingPro, reaffirmed its commitment to ...

BTIG Research decreased their Q1 2025 earnings estimates for shares of Meritage Homes in a report issued on Tuesday, February ...

On Wednesday, BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ...

NEW YORK--(BUSINESS WIRE)--BTIG announced today that it will host its annual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Tuesday, February 11 through Wednesday ...

On Monday, BTIG analyst Andrew Harte maintained a Neutral rating on Global Payments Inc. (NYSE:GPN) stock, despite an approximate 11% increase in share value since the company's third-quarter 2024 ...

Oncocyte will host one-on-one meetings with interested investors. Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to schedule.

Research analysts at BTIG Research reduced their Q4 2025 earnings estimates for shares of D.R. Horton in a research note issued to investors on Tuesday, January 28th. BTIG Research analyst C.

To schedule a one-on-one meeting, investors are encouraged to contact their BTIG representative. This press release includes forward-looking statements that involve risk and uncertainties.